What were the key takeaways from Guardant Health's earnings call?

What factors drove the changes in Guardant Health's revenue and profit?

What does Guardant Health do and what are its main business segments?

What is the revenue and EPS growth rate for Guardant Health year over year?

What guidance did Guardant Health's management provide for the next earnings period?

What is the market's earnings forecast for Guardant Health next quarter?

What were the key takeaways from Guardant Health’s earnings call?

What is Guardant Health's latest dividend and current dividend yield?

- **Revenue Growth**: 2025 total revenue $982 million (+33% YoY), oncology $683.6 million (+26%), screening $79.7 million, biopharma $210.1 million (+18%).
- **Oncology Momentum**: Guardant360 liquid +25% YoY, Reveal fastest-growing product, Guardant360 tissue strengthened post-upgrade.
- **Shield Success**: 38,000 Q4 tests (39% YoY), 93% adherence, MCD expansion to 9 cancers, TRICARE coverage.
- **Financial Health**: 2026 guide $1.25-$1.28 billion revenue, core business free cash flow positive, NovaSeq X to improve margins.
- **Strategic Moves**: MetaSight acquisition, Merck collaboration, Quest/PathGroup partnerships, MCD data collection for FDA approval.

**【CEO Summary Section】**
- **Breakout Year Performance**: 2025 revenue reached $982 million, up 33% YoY, driven by oncology, screening, and biopharma growth. Oncology revenue grew 26% to $683.6 million, screening revenue hit $79.7 million in its first full year, and biopharma revenue rose 18% to $210.1 million.
- **Oncology Growth Drivers**: Guardant360 liquid volumes increased 25% YoY, Reveal became the fastest-growing product, and Guardant360 tissue volumes strengthened post-Smart Platform upgrade. Reveal MRD adoption accelerated with Medicare CRC surveillance coverage.
- **Screening Success**: Shield achieved 38,000 Q4 tests (39% YoY growth) with 93% adherence rate, exceeding expectations. Expansion to multi-cancer detection (MCD) with 9 cancer types launched in Q4, supported by TRICARE coverage and Quest/PathGroup collaborations.
- **R&D and Partnerships**: Acquired MetaSight Diagnostics for advanced MCD tech, and secured 200+ biopharma partnerships, including a multiyear Merck collaboration. Infinity AI developed 15 Smart Apps, enhancing clinical utility.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: Total revenue $281.3 million (+39% YoY). Non-GAAP gross margin improved to 66% (63% YoY), driven by Reveal cost reduction (>$1,000 to <$500/test) and Shield gross margin of 52%. Operating expenses $260 million (+21% YoY), with $64.9 million adj. EBITDA loss.
- **2026 Guidance**: Revenue $1.25-$1.28 billion (+27-30%), with oncology up 25-27%, screening $162-$174 million (210,000-225,000 tests). Free cash flow burn $185-$195 million, improving from $233 million in 2025. Core business (excluding screening) expected to be free cash flow positive.
- **Cost Optimization**: NovaSeq X transition for Guardant360 liquid to reduce costs, targeting 200bps gross margin improvement. Shield ASP maintained at $850, with focus on Medicare-covered lives.

**【Q&A Highlights】**
- **Reveal Therapy Monitoring**: Early uptake in late-stage response monitoring, with potential for ESR1 monitoring in breast cancer post-SERENA-6 trial. Reveal Ultra launch expected in 2026 with best-in-class sensitivity.
- **Shield Growth**: 2026 guide reflects 1Q seasonality but strong back-half momentum. Quest/PathGroup collaborations to enhance EMR integration, with potential co-promotion upside. ACS guideline inclusion and international expansion (Abu Dhabi) as long-term drivers.
- **MetaSight Impact**: Acquisition to accelerate MCD pipeline and enhance CRC screening, with $59 million upfront and $90 million contingent on milestones.
- **Regulatory Strategy**: Shield MCD data collection from 100,000+ patients to support FDA approval, with focus on early-stage cancer detection utility.

Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript

- **Revenue Milestone**: Q3 2025 revenue of $265 million marks first $1 billion annualized run rate, up 39% YoY.
- **Screening Success**: Shield generated $24 million in Q3, with 24,000 tests and 8,000 sequential growth QoQ. MCD launched nationwide with 99% specificity.
- **Gross Margin Expansion**: Non-GAAP gross margin improved to 66%, driven by Shield (55% margin) and Reveal cost reductions (<$500/test COGS).
- **Strategic Partnerships**: Quest Diagnostics and PathGroup collaborations to accelerate Shield adoption, targeting 80,000+ 2025 tests.
- **Pipeline Progress**: PMA submission for Guardant360 Liquid, Reveal Ultra launch in 2026, and MCD data collection for FDA submission in 2027.

**【CEO Summary Section】**
- Q3 2025 revenue grew 39% YoY to $265 million, crossing $1 billion in annualized revenue for the first time.
- Oncology volumes increased 40% YoY to 74,000 tests, driven by Guardant360 Liquid, Tissue, and Reveal.
- Screening revenue reached $24 million with 24,000 Shield tests, tracking at a $100 million annual run rate.
- Biopharma business grew 18% YoY, with 2 new CDx approvals and 23 total claims.
- Launched 15 Smart apps on Guardant360 Liquid, with dozens more in development.
- Submitted PMA for Guardant360 Liquid, targeting FDA approval and ADLT designation.
- Shield Multi-Cancer Detection (MCD) launched nationwide, with 9,251 real-world data points showing 99% specificity and 41% PPV.
- Partnered with Quest Diagnostics and PathGroup to accelerate commercial infrastructure.

**【CFO Financial Commentary】**
- Non-GAAP gross margin improved to 66% (Q3 2025 vs. 63% Q3 2024), driven by Shield (55% margin) and Reveal (COGS < $500/test).
- Operating expenses increased 22% YoY to $28.8 million, reinvesting screening gross profit in sales & marketing.
- Adjusted EBITDA loss narrowed to $45.5 million (vs. $56.2 million prior year), with core business generating positive free cash flow one quarter ahead of target.
- Full-year 2025 revenue guidance raised to $965-$970 million (+31% YoY), including Shield revenue of $71-$73 million.
- Free cash flow burn expected at $225-$235 million for 2025, improving from $275 million in 2024.

**【Q&A Highlights】**
- **Shield ASP Dynamics**: Maintaining $1,495 Medicare rate, with 55% of volume in Q3 at >$800 ASP. Expect gradual decline to $700 by 2028 as commercial mix grows.
- **ACS Guideline Inclusion**: Optimistic about potential inclusion in near term, but not factored into 2025 guidance. Florida Medicaid mandate and federal focus on prevention may accelerate reimbursement.
- **Reveal Growth**: 30%+ YoY volume growth, with 4.5+ tests per patient in longitudinal care. Ultra-sensitive Reveal Ultra launch planned for 2026.
- **MCD Regulatory Path**: Collecting real-world data from 9,251 patients to support FDA submission in late 2027. Early MCD attach rate >50% among Shield orders.
- **Oncology Pipeline**: Guardant360 Liquid PMA submission, Reveal therapy monitoring data submission to MolDX, and 5+ tumor types in MRD studies.

Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 revenue up 31% YoY to $232M, with oncology (+22%), biopharma (+28%), and screening (+400%) leading growth.
- **Product Momentum**: Guardant360 Tissue ASP reached $2,000, Shield achieved 90% patient adherence, and Reveal volume growth accelerated.
- **Financial Strength**: Gross margin improved to 66%, Shield gross margin turned positive at 48%, and free cash flow burn reduced to $65.9M Q2.
- **Strategic Wins**: NCCN guidelines inclusion for Shield, FDA Breakthrough for Shield MCD, and ASCO-featured SERENA-6 trial for breast cancer monitoring.

**【CEO Summary Section】**
- **Q2 Revenue Growth**: Total revenue reached $232 million, up 31% YoY, driven by oncology ($159M, +22%), biopharma ($56M, +28%), and screening ($15M). Guardant360 Liquid volume grew over 20% YoY, while Reveal was the fastest-growing oncology product.
- **Product Highlights**: Guardant360 Tissue ASP hit $2,000 (3 years ahead of target), and Shield achieved 90% patient adherence. ASCO 2025 showcased the SERENA-6 trial, highlighting liquid biopsy's role in breast cancer monitoring.
- **Strategic Initiatives**: NCCN guidelines included Shield in CRC screening, and Shield MCD received FDA Breakthrough Device designation. Reveal's Medicare CRC surveillance coverage expanded volume growth.

**【CFO Financial Commentary】**
- **Financial Performance**: Non-GAAP gross margin improved to 66%, up from 60% YoY, driven by higher ASPs and cost controls. Shield gross margin rose to 48% (vs. 18% Q1), with ASP over $900.
- **Cost Management**: Reveal cost per test dropped below $500 (from >$1,000 in 2024). Sales and marketing expenses increased 45% to $107.8M, supporting commercial expansion.
- **Guidance Update**: Full-year 2025 revenue raised to $915-925M (+24-25% YoY), with Shield revenue guidance revised to $55-60M (vs. $40-45M prior).

**【Q&A Key Highlights】**
- **Reimbursement & Growth**: Shield ASP expected to stabilize at $800 in H2, with Medicare Advantage rates supporting high reimbursement. Reveal's Medicare coverage for breast cancer monitoring is under review.
- **Product Pipeline**: Shield V2 development continues, with potential for multi-cancer detection beyond CRC. Reveal's tests per patient rate is expected to rise with expanded use cases.
- **Market Penetration**: Oncology sales growth driven by Smart Liquid Biopsy's clinical utility, with 30% YoY volume increase. Biopharma partnerships and Infinity platform adoption are key growth drivers.

Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript

- **Revenue Beat**: Q1 2025 total revenue $203.5M (+21% YoY), driven by Oncology (+20%) and Screening launch. 
- **Gross Margin Turnaround**: Reveal and Shield both achieved gross margin positivity in Q1, with COGS reductions >50%. 
- **Product Innovation**: Guardant360 Tissue (40% less tissue req’d) and Shield MCD (60% sensitivity across 10 cancers) set new standards in oncology. 
- **Pipeline Catalysts**: 18 AACR abstracts, NCI Vanguard study, and potential ACS guideline inclusion for Shield MCD. 
- **Cash Flow Improvement**: 2025 free cash burn guided to $225-235M (vs. $275M 2024), with non-screening business on track for Q4 breakeven. 


**【CEO & Co-CEO Summary】**
- **Q1 2025 Total Revenue**: $203.5M (+21% YoY), driven by Oncology ($150.6M, +20%), Biopharma & Data ($45.4M, +21%), and Screening ($5.7M, Shield launch). 
- **Oncology Growth**: Guardant360 volumes +25% YoY to 59,000 tests; ASP improved to $3,000-$3,100 due to Medicare Advantage & commercial reimbursement. Reveal became gross margin positive with COGS reduction >50%. 
- **New Products**: Guardant360 Tissue (multi-omic tissue CGP) launched, requiring 40% less tissue than competitors. Shield (CRC screening) achieved $1,495 Medicare ASP post-ADLT status, with Q1 gross margin positive. 
- **Pipeline Momentum**: 18 AACR abstracts highlight Infinity AI applications (e.g., tumor burden quantification, HRD detection). Shield MCD selected for NCI Vanguard study with 60% sensitivity across 10 cancers. 

**【CFO Financial Highlights】**
- **Non-GAAP Gross Margin**: 65% (vs. 63% Q1 2024), driven by improved oncology ASPs and Reveal/Shield COGS reductions. 
- **Operating Expenses**: $199.6M (+13% YoY), with R&D/G&A flat vs. prior year, reflecting operational leverage. 
- **Cash Flow**: Q1 free cash burn $67M (timing-adjusted improvement vs. Q1 2024). Full-year 2025 guidance: $880-890M revenue (+19-20% YoY), with Screening revenue raised to $40-45M (vs. prior $25-30M). 
- **Long-Term Outlook**: Target 2028 cash flow breakeven, with $450-550M cumulative free cash outflow over 2025-2027. 

**【Q&A Key Takeaways】**
- **Oncology Acceleration**: Guardant360 +25% YoY volumes, Reveal +30% YoY, driven by Medicare CRC surveillance coverage and gross margin positivity. TissueNext ASP ~$1,700-$1,800, with potential share gains via multi-omic integration. 
- **Shield Expansion**: 2025 guidance raised to 52-58K tests (vs. 45-50K), enabled by ADLT ASP of $1,495 and VA coverage for 9M+ patients <65. MCD pipeline includes ACS guideline submission and Vanguard study launch. 
- **Cash Management**: Reinvesting $10M+ from ADLT in screening infrastructure; non-screening business to burn ~$25-35M in 2025, targeting Q4 breakeven. 


Guardant Health (GH)-30 Apr 25-2025 Q1 Earnings call transcript

- **Record Revenue Growth**: Q4 2024 revenue up 30% YoY to $202M, full-year $739M (+31%). Oncology clinical revenue driven by Guardant360 (+24% Q4, +20% full-year). 
- **Cost Efficiency**: Reveal COGS reduced 50%, Shield gross margin breakeven in Q4. Full-year non-GAAP gross margin 62%. 
- **Pipeline Momentum**: Shield V2 launch late 2025, Abu Dhabi partnership targets 10k+ annual tests. 2025 free cash flow burn to improve 25% to $225-235M. 
- **Strategic Wins**: FDA approval for Shield, Medicare coverage for Reveal CRC surveillance, $293M litigation award. 


**【Helmy Eltoukhy - 2024 Year-in-Review】**
- **Revenue Growth**: Q4 2024 revenue reached $202 million (30% YoY), full-year $739 million (31% YoY). Oncology clinical revenue grew 34% YoY, driven by Guardant360 volume (+24% Q4, +20% full-year) and ASP improvements ($3,000 in H2 vs $2,770 Q4 2023). 
- **Product Upgrades**: Guardant360 Liquid (Smart LBP) expanded gene coverage 10x and sensitivity 10x, leading to mid-single-digit sequential volume growth. Reveal achieved 50% COGS reduction, enabling gross margin breakeven. 
- **Market Expansion**: Shield (FDA-approved CRC screening) generated $4.1M Q4 revenue, 65%+ Medicare mix, and $920 ASP. Abu Dhabi partnership targets 10,000+ annual tests post-phase 1 ramp. 

**【AmirAli Talasaz - Screening Update】**
- **Shield Performance**: Q4 2024 ASP $600 (COGS $600), gross margin breakeven. 2025 guidance: $25-30M revenue (45-50k tests), back-end loaded due to 100+ rep ramp. Abu Dhabi volumes ~10% of guide. 
- **Pipeline Catalysts**: Shield V2 launch expected late 2025, NCCN/MolDX updates for breast/lung monitoring, and potential ADLT rate ($1,495 vs $920). 

**【Mike Bell - Financial Highlights】**
- **2024 Results**: Non-GAAP gross margin 62% (vs 61% 2023), adj. EBITDA loss $258M (improvement of $86M). Free cash flow burn $275M (vs $345M 2023). 
- **2025 Outlook**: Revenue $850-860M (+15-16%), Oncology +15%, Biopharma low double-digit. Free cash flow burn $225-235M (-15%), with core Oncology cash flow positive. 
- **Balance Sheet**: $944M cash post-convertible debt refinancing. 2028 breakeven target with $450-550M cumulative outflow. 

**【Q&A Key Takeaways】**
- **Reveal Adoption**: 2025 volumes expected to accelerate post-Medicare coverage, with ASP ~$600 (excluding ADLT). Tumor-informed and tissue-free MRD dual strategy. 
- **Shield ASP**: 2025 guidance excludes ADLT upside, but ~$920 Medicare rate stable. Commercial payer engagement to begin post-ACS guidelines. 
- **Litigation Win**: $293M jury award for false advertising case, no material financial impact. 


Actual							-0.29	-0.57	-0.78	-0.94	-0.49	-0.61	-1.06	-0.89	-1.21	-2.25	-1.58	-1.36	-1.3	-0.67	-0.73	-1.58	-0.94	-0.84	-0.88	-0.9	-0.77	-0.8	-0.74	-1
Forecast							-0.3936	-0.3683	-0.3854	-0.5673	-0.8866	-0.8191	-0.8831	-1.1083	-1.2133	-1.2141	-1.2806	-1.4013	-1.3377	-1.2172	-0.9675	-0.8621	-0.8792	-0.7535	-0.7304	-0.7772	-0.7857	-0.7405	-0.7896	-0.7668
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+26.32%	-54.77%	-102.39%	-65.70%	+44.73%	+25.53%	-20.03%	+19.70%	+0.27%	-85.32%	-23.38%	+2.95%	+2.82%	+44.96%	+24.55%	-83.27%	-6.92%	-11.48%	-20.48%	-15.80%	+2.00%	-8.04%	+6.28%	-30.41%

GH

GH fundamentals

GH Q4 2025 Earnings

Earnings Call

You can ask Aime

GH

GH fundamentals

GH Q4 2025 Earnings

Earnings Call

GH Earnings Call Summary for Q4/20254:30 PM on Feb 19, 2026

GH Earnings Call Summary for Q3/20254:30 PM on Oct 29, 2025

GH Earnings Call Summary for Q2/20254:30 PM on Jul 30, 2025

GH Earnings Call Summary for Q1/20254:30 PM on Apr 30, 2025

GH Earnings Call Summary for Q4/20244:30 PM on Feb 20, 2025

You can ask Aime